Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-2307
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancer ; volume:481 ; number:1 ; day:28 ; month:4 ; year:2022 ; pages:83-92 ; date:7.2022
Virchows Archiv ; 481, Heft 1 (28.4.2022), 83-92, 7.2022
- Creator
-
Garczyk, Stefan
Degener, Stephan
Bischoff, Felix
Schnitzler, Tician
Salz, Anne
Golz, Reinhard
Buchner, Alexander
Schulz, Gerald B.
Schneider, Ursula
Gaisa, Nadine T.
Knüchel, Ruth
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00428-022-03328-1
- URN
-
urn:nbn:de:101:1-2022081718462159771310
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:37 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Garczyk, Stefan
- Degener, Stephan
- Bischoff, Felix
- Schnitzler, Tician
- Salz, Anne
- Golz, Reinhard
- Buchner, Alexander
- Schulz, Gerald B.
- Schneider, Ursula
- Gaisa, Nadine T.
- Knüchel, Ruth
- SpringerLink (Online service)
Other Objects (12)
Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancer
Intravesical thermochemotherapy in the treatment of high-risk and very high-risk non-muscle-invasive urothelial bladder cancer: a single-arm study
Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder : implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer
Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer
Molecular classification of urothelial bladder carcinoma
SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016)
SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018)
High-Risk Non-Muscle-Invasive Bladder Cancer—Therapy Options During Intravesical BCG Shortage
Chromosomal imbalance in the progression of high-risk non-muscle invasive bladder cancer
Efficacy and safety of tislelizumab plus bacillus-calmette guérin with or without chemotherapy as a bladder-sparing treatment for high-risk non-muscle-invasive bladder urothelial cancer: a real-world study
CD10 expression in urothelial carcinoma of the bladder
Young age increases the risk of lymph-node metastasis in patients with muscle-invasive bladder urothelial carcinoma
Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancer
Intravesical thermochemotherapy in the treatment of high-risk and very high-risk non-muscle-invasive urothelial bladder cancer: a single-arm study
Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder : implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer
Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer
Molecular classification of urothelial bladder carcinoma
SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016)
SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018)
High-Risk Non-Muscle-Invasive Bladder Cancer—Therapy Options During Intravesical BCG Shortage
Chromosomal imbalance in the progression of high-risk non-muscle invasive bladder cancer
Efficacy and safety of tislelizumab plus bacillus-calmette guérin with or without chemotherapy as a bladder-sparing treatment for high-risk non-muscle-invasive bladder urothelial cancer: a real-world study
CD10 expression in urothelial carcinoma of the bladder
Young age increases the risk of lymph-node metastasis in patients with muscle-invasive bladder urothelial carcinoma
Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancer
Intravesical thermochemotherapy in the treatment of high-risk and very high-risk non-muscle-invasive urothelial bladder cancer: a single-arm study
Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder : implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer
Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer
Molecular classification of urothelial bladder carcinoma
SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016)
SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018)
High-Risk Non-Muscle-Invasive Bladder Cancer—Therapy Options During Intravesical BCG Shortage
Chromosomal imbalance in the progression of high-risk non-muscle invasive bladder cancer
Efficacy and safety of tislelizumab plus bacillus-calmette guérin with or without chemotherapy as a bladder-sparing treatment for high-risk non-muscle-invasive bladder urothelial cancer: a real-world study
CD10 expression in urothelial carcinoma of the bladder